Managing hyperlipidaemia

Practitioner

Volumn 248, Issue 1662, 2004, Pages 660-668

  Wang, Tim W M ^a,b,c  

^a FRIMLEY PARK HOSPITAL   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; HYPERLIPIDEMIA; MIDDLE AGED; RISK ASSESSMENT;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MIDDLE AGED; RISK ASSESSMENT;

EID: 16644397935     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. 45 Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-1307
3. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on detection, evaluation and treatment of high blood cholesterol in adults. Heart 1998;80(suppl 2):S1-S29
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
5. De Backer G, Ambrosioni E, Borch-Johnsen K et al. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention. Eur Heart J 2003;24:1601-1610
6. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229-234
7. Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20(4):614-620
8. Sever PS, Dahlof B, Poulter NR et al, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-1158
9. The Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
10. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630
11. GISSI-Prevenzione Investigators. Dietary supplements with n-3 polyunsaturated fatty acid and vitamin E after myocardial infarction: results of the GISS-Prevenzione trial. Lancet 1999;354:447-455